drugset
drugset / Trial / NCT04988997

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

NCT04988997 ↗

Phase 2 Terminated 12 enrolled 9 Meters Biopharma, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.

Timeline

Start
2021-06-14
Primary completion
2022-08-05
Completion
2022-08-24

Outcome

Outcome not reported

Stopped: “Trial terminated by Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vurolenatide Protein / enzyme biologic 50 mg Subcutaneous
Comparator Vurolenatide Protein / enzyme biologic 100 mg Subcutaneous

Indications

short bowel syndrome